Isolated in-vivo lung perfusion for treatment of lung cancer
Reference number | |
Coordinator | Xvivo Perfusion Aktiebolag |
Funding from Vinnova | SEK 343 000 |
Project duration | December 2014 - August 2015 |
Status | Completed |
Important results from the project
This pre-project aimed to evaluate the feasibility of treating lung cancer by isolating the lung in-situ and perfusing the isolated lung with very hight doses of chemotherapy. This is supposedly achieved by perfusing the isolated lung with STEEN Solution which functions as carrier for the high dose chemotherapy.
Expected long term effects
We anticipated that IVLP with STEEN Solution as perfusate would result in fewer procedural complications compared to existing treatment of lung cancer patients. Our pre-study showed that this is most likely feasible, but further testing needs to be performed to validate the concept before we perform study on patients.
Approach and implementation
The pre-study was performed in collaboration with two leading clinics in Europe, and results of the pre-study forms a basis for initiation of a full in-vivo study on human subjects.